{
    "clinical_study": {
        "@rank": "60409", 
        "arm_group": [
            {
                "arm_group_label": "Immune Thrombocytopenics", 
                "description": "The study shall be a single institution prospective cohort study. Comparison will be made between individuals with known ITP versus those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy induced thrombocytopenia, and myelodysplastic thrombocytopenia]."
            }, 
            {
                "arm_group_label": "hypo-proliferative thrombocytopenics", 
                "description": "The study shall be a single institution prospective cohort study. Comparison will be made between individuals with known ITP versus those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy induced thrombocytopenia, and myelodysplastic thrombocytopenia]."
            }
        ], 
        "biospec_descr": {
            "textblock": "Study subjects will have the following collected: Lavender tri-potassium EDTA tubes filled\n      according to the manufacturer's specifications [approximately 4ML of venous blood], labeled,\n      and promptly dispatched to the laboratory.The sample will be gently inverted several times\n      prior to analysis on the ADVIA 120 taking care not to overly agitate the sample. Moreover,\n      the specimen shall be inspected for clot formation prior to being assayed. The full blood\n      count shall be obtained and in the configuration sub-menu the extended platelet parameter\n      option shall be selected and thus actuated. A print out will be generated including the MPC,\n      MPM, platelet component distribution width, platelet mass distribution width, and large\n      platelet count in addition to the standard platelet count and mean platelet volume [MPV]."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia\n      (ITP) from hypo-proliferative causes of thrombocytopenia.\n\n      To develop the clinical potential of the extended platelet parameters as they pertain to\n      distinguishing different causes of thrombocytopenia from one another.\n\n      To test the hypothesis that mean platelet component concentration and mean platelet mass\n      might distinguish between thrombocytopenia related to bone marrow dysfunction and immune\n      mediated destruction of platelets."
        }, 
        "brief_title": "Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Immune Thrombocytopenia", 
            "Chemotherapy Induced Thrombocytopenia", 
            "Myelodysplasia Related Thrombocytopenia", 
            "Aplastic Anaemia Related Thrombocytopenia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Anemia, Aplastic", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Thrombocytopenia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patient to be registered at the Haematology-Oncology department St Luke's Roosevelt Hospital\n      Centre.\n\n      Inclusion criteria are as follows:\n\n      All individuals age 18yrs and above capable of rendering consent Known ITP confirmed by\n      response to IVIG, glucocorticoids, or winRho and exclusion of all other possible causes of\n      thrombocytopenia Confirmed aplastic anemia [as assessed through bone marrow trephine biopsy]\n      Chemotherapy induced thrombocytopenia assessed at time of predicted nadir."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All individuals age 18yrs and above capable of rendering consent\n\n          -  Known ITP confirmed by response to intravenous immune globulin (IVIG),\n             glucocorticoids, or winRho and exclusion of all other possible causes of\n             thrombocytopenia\n\n          -  Confirmed aplastic anemia [as assessed through bone marrow trephine biopsy]\n\n          -  Chemotherapy induced thrombocytopenia assessed at time of predicted nadir.\n\n        Exclusion Criteria:\n\n          -  Suspected multifactorial thrombocytopenias and thrombocytopenia due to hypersplenism\n\n          -  Chronic active hepatitis\n\n          -  Those infected with HIV\n\n          -  Patients receiving concomitant radiotherapy\n\n          -  Gravid females\n\n          -  Congenital thrombocytopenias"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study population would consist of adult female and male subjects of all ethnic\n        persuasions in good general health apart from thrombocytopenia, bone marrow aplasia,\n        myelodysplasia, or active malignancy requiring therapy.  Vulnerable strata of the hospital\n        population will not be recruited into the study."
            }
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01933035", 
            "org_study_id": "13-0134"
        }, 
        "intervention": {
            "arm_group_label": [
                "Immune Thrombocytopenics", 
                "hypo-proliferative thrombocytopenics"
            ], 
            "intervention_name": "Full blood count with extended platelet parameters", 
            "intervention_type": "Other", 
            "other_name": [
                "The MPC is rendered as follows: MPC (g/dl) = (RI - 1.333)/0.0018 dl/g [27 +/- 2 g/dL]", 
                "Mean platelet mass [MPM] in pg [2.0 +/- 1.0]."
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ITP", 
            "Thrombocytopenia", 
            "mean platelet mass", 
            "mean platelet component"
        ], 
        "lastchanged_date": "March 7, 2014", 
        "location": {
            "contact": {
                "email": "Mvarma@chpnet.org", 
                "last_name": "Mala Varma, MD", 
                "phone": "212-523-2180"
            }, 
            "contact_backup": {
                "email": "tmirzoye@chpnet.org", 
                "last_name": "Tahir Mirzoyev", 
                "phone": "212 523 7289"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10019"
                }, 
                "name": "Roosevelt Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Mala Varma, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Hrvoje Melinscak, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.", 
        "other_outcome": {
            "measure": "Platelet mass distribution width", 
            "safety_issue": "No", 
            "time_frame": "12 Months"
        }, 
        "overall_contact": {
            "email": "Mvarma@chpnet.org", 
            "last_name": "Mala Varma, MD", 
            "phone": "212 523 2180"
        }, 
        "overall_contact_backup": {
            "email": "hmelinscak@chpnet.org", 
            "last_name": "Hrvoje Melinscak, MD", 
            "phone": "212 523 8741"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Increased platelet density", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01933035"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "mean platelet mass", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Beth Israel Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beth Israel Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "12 Months", 
        "verification_date": "March 2014"
    }
}